Thin
High-Quality Cargrilintide CAS 1415456-99-3 – US Market Supply
- Sequence Type: Long-acting Amylin Analogue
- Physical State: Lyophilized White Powder
- Documentation: CoA, HPLC, LC-MS, Q-TOF
- Lead Time: US Hub Ready / Fast Courier
Pre-formulation and commercial-grade synthetic peptides synthesized under rigorous QA/QC parameters, supporting preclinical investigations, clinical scale-up, and therapeutic innovation throughout North America.
The United States biopharmaceutical sector is undergoing an unprecedented paradigm shift. Driven by the meteoric rise of GLP-1, GIP, and glucagon multi-agonists for type 2 diabetes mellitus, metabolic dysfunction-associated steatohepatitis (MASH), and chronic weight management, traditional supply chain architectures are failing to keep pace with clinical consumption.
According to FDA drug shortage databases, the compounding landscape governed under 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) has witnessed persistent shortages of finished injectable incretins. As innovator pharma scales internal drug substance manufacturing, clinical pipeline programs and compounding pharmacies face extreme supply crunches, inflated active pharmaceutical ingredient (API) markups, and unstable batch yields.
Simultaneously, North American venture-backed biotechnology hubs in Boston, San Diego, and San Francisco demand peptide entities characterized by complex post-translational mimics: lipidation via multi-step fatty acid side chains (e.g., C18 diacid, C20 diacid), cyclic conformation via lactam bridging, and unnatural amino acid insertions (Aib, D-enantiomers). Meeting this dual imperative of extreme volume and delicate structural purity requires manufacturing infrastructure operating at China Factory 4.0 standards.
Every gram routed to the United States market undergoes dual-sample stability retention, validated temperature logging (-20°C to -80°C lyophilized transport), and direct customs manifest clearance via expedited air corridors (JFK, ORD, LAX).
How our advanced industrial infrastructure overcomes the historical constraints of solid-phase peptide synthesis (SPPS), delivering 40%–60% operational efficiencies to North American pharmaceutical buyers.
Equipped with 500L, 1,000L, and 3,000L glass-lined jacketed solid-phase reactors. Real-time optical monitoring of amino acid deprotection (UV-monitored Fmoc removal) guarantees near-quantitative coupling yields (>99.2% per cycle) even across sterically hindered sequences reaching 40+ amino acids.
Operating multi-axis preparative chromatography skids using high-pressure axial compression columns (DAC 300mm to DAC 800mm). This multi-stage gradient elution separates critical deletion impurities, diastereomers, and beta-aspartyl peptides, yielding exceptional chromatographic resolution.
Equipped with Class A cleanroom freeze-drying suites featuring automated SIP/CIP systems. Full technical capability to swap trifluoroacetate (TFA) salts to bio-compatible acetate or hydrochloride forms, satisfying FDA expectations regarding residual organofluorine levels in parenteral therapies.
Meeting corporate ESG criteria and reducing synthesis footprint for forward-thinking US drug development sponsors.
Replacing hazardous N,N-dimethylformamide (DMF) and N-methyl-2-pyrrolidone (NMP) with bio-based Cyrene and 2-MeTHF in commercial peptide coupling protocols, reducing PMI (Process Mass Intensity) by 54%.
Implementing engineered ligases for segment condensation of long peptides (such as Semaglutide, Tirzepatide, and Survodutide), avoiding steric aggregation and doubling pure batch yields.
Transitioning high-volume cosmetic and veterinary peptides to automated continuous-flow liquid-phase synthesis (LPPS) to achieve sub-second heat/mass transfer and zero off-spec batch run-rates.
North American biotechs frequently encounter a common pitfall: early discovery peptides produced via small-scale microwave synthesizers suffer from disastrous impurity escalations when scaled to 5-kilogram pilot batches.
Our process chemists eliminate scale-up discrepancies by establishing critical quality attributes (CQAs) at the milligram development phase. Utilizing Design of Experiments (DoE), we optimize resin cross-link density, linker kinetics (CTC vs. Wang resin), coupling activators (DIC/Oxyma vs. HATU), and cleavage scavenger cocktails (EDT, TIS, water, phenol) to suppress epimerization (D-amino acid conversion) below 0.1%.
Waters Acquity UPLC with PDA & QDa Mass Detection • Agilent 6545 LC/Q-TOF for high-resolution monoisotopic confirmation • Headspace Gas Chromatography (HS-GC) for residual organic solvents (ICH Q3C) • Endosafe nexgen-PTS for kinetic chromogenic endotoxin measurement.
A transparent overview of the quality data packages and regulatory files provided to US buyers for fast-track vendor qualification.
| Analytical Parameter | Pharmacopeial Test Method | Thinheal US Standard Specification | Significance for US Formulation |
|---|---|---|---|
| HPLC Chromatographic Purity | Reverse-Phase UPLC / HPLC (USP <621>) | ≥98.0% to ≥99.5% | Eliminates D-enantiomers & deletion peptides that compromise efficacy. |
| Peptide Identification | ESI-MS / MALDI-TOF / LC-MS-MS | Exact Monoisotopic Mass Match (±0.5 Da) | Confirms sequence integrity and secondary structure validation. |
| Net Peptide Content (Strength) | Elemental Nitrogen Analysis / Quantitative Amino Acid Analysis (AAA) | ≥80.0% to ≥88.0% (Net Content) | Critical for precise clinical dosing calculations (differentiating gross powder vs active peptide). |
| Bacterial Endotoxin Level | Kinetic Chromogenic LAL (USP <85>) | <0.05 EU/mg (Custom down to <0.005) | Essential for parenteral dosage compliance and pyrogen-free animal models. |
| Residual Solvents | Headspace Gas Chromatography (USP <467>) | Meets ICH Q3C Class 1, 2, & 3 Limits | Limits DMF, ACN, DCM, and ether residues below regulatory safety thresholds. |
| Counter-Ion Profiling | Ion Chromatography (IC) | Acetate / Hydrochloride (<0.1% TFA) | Mitigates cytotoxicity and biological degradation in sensitive cell lines. |
From innovative incretin mimetics and tissue regenerative compounds to high-potency cosmetic signal peptides, each lot is backed by rigorous lot-to-lot consistency protocols.
Expert answers addressing quality control, customs clearance, cGMP registration, cold-chain transport, and minimum order quantities.
We maintain an experienced export logistics department that provides all required documentation for seamless US Customs and Border Protection (CBP) clearance. Every shipment is accompanied by a Toxic Substances Control Act (TSCA) certification, proper Harmonized Tariff Schedule (HTS) code categorization (such as Chapter 2937 or 3002), clear Non-Controlled Substance declarations, and complete commercial invoices. We partner with Tier-1 freight forwarders (FedEx Priority, DHL Medical Express, World Courier) with established pre-clearance clearance protocols.
Yes. While standard solid-phase peptide cleavage utilizes TFA cocktails, we offer automated counter-ion exchange as a routine downstream step. We can convert peptide salts to pure acetate, hydrochloride, or sodium forms, verifying that residual TFA is reduced below 0.1% or non-detectable levels via Headspace Gas Chromatography or ion-exchange chromatography. This step is particularly critical for biological assays, cellular toxicology testing, and formulation development.
Each commercial and research-grade lot is delivered with a comprehensive, batch-specific Certificate of Analysis (CoA). This includes analytical RP-HPLC traces demonstrating purity and related substances, electrospray ionization mass spectrometry (ESI-MS) or high-resolution Q-TOF data confirming sequence mass, Karl Fischer moisture titration results, solubility observations, and, upon request, Bacterial Endotoxin (LAL) testing, amino acid analysis (AAA), and residual solvent profiles.
Thinheal supports clients across the entire lifecycle: from milligram-scale custom research lots (50mg–1g) for sequence feasibility and in vitro screenings, to kilogram and multi-ton campaigns for commercial API formulation and aesthetic brand manufacturing. Our total annual chemical synthesis output exceeds several metric tons, making us one of the largest dedicated peptide manufacturing platforms in China.
Peptides are shipped in high-density, moisture-barrier pharmaceutical vials purged with inert argon gas to prevent oxidation of sensitive residues (e.g., Met, Cys, Trp). Depending on compound sensitivity, shipments are routed in qualified VIP (Vacuum Insulated Panel) thermal packaging maintained with certified phase-change cold packs (-20°C) or solid carbon dioxide (dry ice, -78.5°C), supplemented with real-time USB/NFC temperature data loggers.
Yes. In addition to our commercial hot products catalog, our Hangzhou R&D center provides comprehensive peptide CDMO solutions. Our expertise encompasses complex branched peptides, fatty acid lipidations (such as mono- and di-acids for albumin binding), PEGylation, isotope labeling, stapled alpha-helical peptides, cyclic disulfide bridges, and non-natural amino acid insertions with full analytical method development.